ClinicalTrials.gg

Program

AltSonflex1-2-3

Also written as “altSonflex1-2-3 Dose A”, “altSonflex1-2-3 Dose B” and “altSonflex1-2-3 Dose C”.

Its studies are mostly in Diarrhea, led by GlaxoSmithKline.

Furthest: phase 2, since Sep 29, 20213 company-led studies, 1 open or runningNext primary completion: Oct 16, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline31 open or runningphase 2since Sep 29, 2021Sep 29, 2021Oct 16, 2028phase 2 · NCT07320716

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 29, 2021First study: phase 2 study in DiarrheaFirst studyNCT05073003 · 551 enrolled · Belgium, Kenya
  2. Oct 25, 2024Phase 2 study in DiarrheaNCT06663436 · 200 enrolled · Kenya
  3. Dec 22, 2025Phase 2 study in DiarrheaNCT07320716 · 179 planned · Kenya

Ahead

  1. Oct 16, 2028Primary completion: phase 2 study in DiarrheaNCT07320716

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07320716Diarrhea · Kenya2RecruitingOct 16, 2028179
NCT06663436Diarrhea · Kenya2CompletedOct 21, 2025200
NCT05073003Diarrhea · Belgium, Kenya2CompletedJun 24, 2025551

How it is read

Names in the registry

  • “AltSonflex1-2-3”, 1 entry
  • “altSonflex1-2-3 Dose A”, 1 entry
  • “altSonflex1-2-3 Dose B”, 1 entry
  • “altSonflex1-2-3 Dose C”, 1 entry
  • “AltSonflex1-2-3 High Dose”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
AltSonflex1-2-3 (GlaxoSmithKline): development program | ClinicalTrials.gg